Angiotensin-Converting Enzyme Inhibition Improves Cardiac Function: Role of Bradykinin

• Published in: Hypertension (Dallas, Tex. 1979) Vol. 23; no. 4; pp. 411 - 418
• Main Authors: Gohlke, Peter, Linz, Wolfgang, Schölkens, Bernward A, Kuwer, Ingo, Bartenbach, Susanne, Schnell, Angela, Unger, Thomas
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01.04.1994; Hagerstown, MD Lippincott
• Subjects: Adenosine Triphosphate - metabolism; Administration, Oral; Animals; Antihypertensive agents; Biological and medical sciences; Bradykinin - analogs & derivatives; Bradykinin - antagonists & inhibitors; Bradykinin - pharmacology; Bradykinin - physiology; Bradykinin - therapeutic use; Cardiovascular system; Cerebrovascular Disorders - etiology; Coronary Circulation - drug effects; Creatine Kinase - metabolism; Dose-Response Relationship, Drug; Female; Glycogen - metabolism; Heart - drug effects; Heart - physiopathology; Hypertension - metabolism; Hypertension - physiopathology; Hypertension - prevention & control; Hypertrophy, Left Ventricular - metabolism; Hypertrophy, Left Ventricular - physiopathology; Hypertrophy, Left Ventricular - prevention & control; L-Lactate Dehydrogenase - metabolism; Lactates - metabolism; Male; Medical sciences; Myocardium - enzymology; Myocardium - metabolism; Pharmacology. Drug treatments; Phosphocreatine - metabolism; Pregnancy; Ramipril - administration & dosage; Ramipril - pharmacology; Ramipril - therapeutic use; Rats; Rats, Inbred SHR; Rats, Wistar; Ventricular Pressure - drug effects; Hypertension; Cardiac performance; Rat; Enzyme; Low dose; Cytokine; Rodentia; Enzyme inhibitor; Cardiovascular disease; Hereditary; Long term; Vertebrata; Chemotherapy; Mammalia; Treatment; Peptidyl-dipeptidase A; Animal; Bradykinin; Hydrolases; Peptidyl-dipeptidases; Proteinases; High dose
• ISSN: 0194-911X; 1524-4563
• DOI: 10.1161/01.hyp.23.4.411

The effect of chronic low- and high-dose treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril (0.01 and 1 mg/kg per day) on the development of hypertension and left ventricular hypertrophy as well as on functional and biochemical alterations of the heart was studied in stroke-prone spontaneously hypertensive rats treated prenatally and subsequently up to the age of 20 weeks. The contribution of endogenous bradykinin potentiation to the ACE inhibitor actions was assessed by cotreatment of rats with the bradykinin B2-receptor antagonist Hoe 140 (500 μg/kg per day SC) from 6 to 20 weeks of age. High- but not low-dose ACE inhibitor treatment prevented the development of hypertension and left ventricular hypertrophy. Chronic bradykinin receptor blockade did not attenuate the antihypertensive and antihypertrophic actions of ramipril. High-dose ramipril treatment improved cardiac function, as demonstrated by an increase in left ventricular pressure (29.9%), dP/dtmax (34.9%), and coronary flow (22.1%), without a change in heart rate. The activities of lactate dehydrogenase and creatine kinase and lactate concentration in the coronary effluent were reduced by 39.3%, 55.5%, and 66.7%, respectively. Myocardial tissue concentrations of glycogen and the energy-rich phosphates ATP and creatine phosphate were increased by 31.3%, 39.9%, and 73.7%, respectively, whereas lactate was decreased by 20.8%. Chronic low-dose ACE inhibitor treatment led to a pattern of changes in cardiodynamics and cardiac metabolism similar to that observed with the high dose. All ACE inhibitorinduced effects on cardiac function and metabolism were abolished by chronic bradykinin receptor blockade. Our results demonstrate that chronic ACE inhibitor treatment in stroke-prone spontaneously hypertensive rats improves cardiac function even at low doses that do not affect the development of hypertension and left ventricular hypertrophy. These effects of the ACE inhibitor are due to bradykinin potentiation. However, bradykinin does not seem to contribute to the antihypertensive and antihypertrophic actions of the ACE inhibitor in this model of hypertension.